-
Je něco špatně v tomto záznamu ?
Androgen receptor axis-targeted agents for non-metastatic castration-resistant prostate cancer impact on overall survival and safety profile
K. Mori, F. Quhal, S. Katayama, H. Mostafaei, E. Laukhtina, VM. Schuettfort, R. Sari Motlagh, NC. Grossmann, P. Rajwa, G. Ploussard, A. Briganti, T. Kimura, S. Egawa, R. Papalia, DM. Carrion, C. Fiori, SF. Shariat, F. Esperto, B. Pradere
Jazyk angličtina Země Itálie
Typ dokumentu časopisecké články, metaanalýza
- MeSH
- antagonisté androgenních receptorů * škodlivé účinky MeSH
- kvalita života MeSH
- lidé MeSH
- nádory prostaty rezistentní na kastraci * farmakoterapie patologie MeSH
- protinádorové látky * škodlivé účinky MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- metaanalýza MeSH
INTRODUCTION: The management of non-metastatic castration-resistant prostate cancer (nmCRPC) has undergone a paradigm shift with the development of androgen receptor axis-targeted (ARAT) agents. The updated results with final overall survival (OS) data of the phase III PROSPER, SPARTAN, and ARAMIS trials have recently been reported. Therefore, we performed an updated meta-analysis and network meta-analysis to indirectly compare the efficacy and safety of currently available treatments. EVIDENCE ACQUISITION: Multiple databases were searched for articles published before January 2021. Studies that compared OS and adverse events (AEs) in patients with nmCRPC were considered eligible. EVIDENCE SYNTHESIS: Three studies (N.=4117) met our eligibility criteria. Formal network meta-analyses were conducted. ARAT agent is associated with significantly longer OS compared to placebo (pooled hazard ratio [HR]: 0.74, 95% confidence interval [CI]: 0.65-0.83, P<0.001), with similar results shown for patients with both N1 and N0 disease (pooled HR 0.61 and pooled HR 0.76, respectively). In the network meta-analysis, apalutamide, darolutamide, and enzalutamide were more effective than placebo, with similar efficacies in terms of OS. For AEs (including any AEs, grade 3 or grade 4 AEs, grade 5 AEs, serious AEs, and AEs leading to treatment discontinuation), darolutamide was shown to be likely well tolerated. Quality of Life was preserved in treatment arms irrespective of the drug. CONCLUSIONS: All three ARAT agents are efficacious options for the treatment of nmCRPC, whereas darolutamide appears to have the most favorable tolerability profile. These findings may facilitate individualized treatment strategies and inform future direct comparative trials.
Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic
Department of Urology Campus Bio Medico University Rome Italy
Department of Urology IRCCS San Raffaele Hospital Vita Salute San Raffaele University Milan Italy
Department of Urology King Fahad Specialist Hospital Dammam Saudi Arabia
Department of Urology La Croix du Sud Hospital Quint Fonsegrives France
Department of Urology La Paz University Hospital Madrid Spain
Department of Urology Medical University of Silesia Zabrze Poland
Department of Urology Medical University of Vienna Vienna Austria
Department of Urology University Hospital Zurich Zurich Switzerland
Department of Urology University Medical Center Hamburg Eppendorf Hamburg Germany
Department of Urology University of Texas Southwestern Dallas TX USA
Department of Urology Weill Cornell Medical College New York NY USA
Division of Urology Department of Special Surgery The University of Jordan Amman Jordan
European Society of Residents in Urology Arnhem the Netherlands
Institute for Urology and Reproductive Health Sechenov University Moscow Russia
Karl Landsteiner Institute of Urology and Andrology Vienna Austria
Research Center for Evidence Based Medicine Tabriz University of Medical Sciences Tabriz Iran
School of Medicine Department of Urology Jikei University Tokyo Japan
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22018232
- 003
- CZ-PrNML
- 005
- 20220804134636.0
- 007
- ta
- 008
- 220720s2022 it f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.23736/S2724-6051.21.04431-1 $2 doi
- 035 __
- $a (PubMed)34308608
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a it
- 100 1_
- $a Mori, Keiichiro $u Department of Urology, Medical University of Vienna, Vienna, Austria - keiichiro.mori@meduniwien.ac.at $u School of Medicine, Department of Urology, Jikei University, Tokyo, Japan - keiichiro.mori@meduniwien.ac.at
- 245 10
- $a Androgen receptor axis-targeted agents for non-metastatic castration-resistant prostate cancer impact on overall survival and safety profile / $c K. Mori, F. Quhal, S. Katayama, H. Mostafaei, E. Laukhtina, VM. Schuettfort, R. Sari Motlagh, NC. Grossmann, P. Rajwa, G. Ploussard, A. Briganti, T. Kimura, S. Egawa, R. Papalia, DM. Carrion, C. Fiori, SF. Shariat, F. Esperto, B. Pradere
- 520 9_
- $a INTRODUCTION: The management of non-metastatic castration-resistant prostate cancer (nmCRPC) has undergone a paradigm shift with the development of androgen receptor axis-targeted (ARAT) agents. The updated results with final overall survival (OS) data of the phase III PROSPER, SPARTAN, and ARAMIS trials have recently been reported. Therefore, we performed an updated meta-analysis and network meta-analysis to indirectly compare the efficacy and safety of currently available treatments. EVIDENCE ACQUISITION: Multiple databases were searched for articles published before January 2021. Studies that compared OS and adverse events (AEs) in patients with nmCRPC were considered eligible. EVIDENCE SYNTHESIS: Three studies (N.=4117) met our eligibility criteria. Formal network meta-analyses were conducted. ARAT agent is associated with significantly longer OS compared to placebo (pooled hazard ratio [HR]: 0.74, 95% confidence interval [CI]: 0.65-0.83, P<0.001), with similar results shown for patients with both N1 and N0 disease (pooled HR 0.61 and pooled HR 0.76, respectively). In the network meta-analysis, apalutamide, darolutamide, and enzalutamide were more effective than placebo, with similar efficacies in terms of OS. For AEs (including any AEs, grade 3 or grade 4 AEs, grade 5 AEs, serious AEs, and AEs leading to treatment discontinuation), darolutamide was shown to be likely well tolerated. Quality of Life was preserved in treatment arms irrespective of the drug. CONCLUSIONS: All three ARAT agents are efficacious options for the treatment of nmCRPC, whereas darolutamide appears to have the most favorable tolerability profile. These findings may facilitate individualized treatment strategies and inform future direct comparative trials.
- 650 12
- $a antagonisté androgenních receptorů $x škodlivé účinky $7 D059002
- 650 12
- $a protinádorové látky $x škodlivé účinky $7 D000970
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a nádory prostaty rezistentní na kastraci $x farmakoterapie $x patologie $7 D064129
- 650 _2
- $a kvalita života $7 D011788
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a metaanalýza $7 D017418
- 700 1_
- $a Quhal, Fahad $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Department of Urology, King Fahad Specialist Hospital, Dammam, Saudi Arabia
- 700 1_
- $a Katayama, Satoshi $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Department of Urology, Okayama University, Okayama, Japan
- 700 1_
- $a Mostafaei, Hadi $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Research Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
- 700 1_
- $a Laukhtina, Ekaterina $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia
- 700 1_
- $a Schuettfort, Victor M $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- 700 1_
- $a Sari Motlagh, Reza $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Men's Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
- 700 1_
- $a Grossmann, Nico C $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Department of Urology, University Hospital Zurich, Zurich, Switzerland
- 700 1_
- $a Rajwa, Pawel $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Department of Urology, Medical University of Silesia, Zabrze, Poland
- 700 1_
- $a Ploussard, Guillaume $u Department of Urology, La Croix du Sud Hospital, Quint Fonsegrives, France
- 700 1_
- $a Briganti, Alberto $u Department of Urology, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy
- 700 1_
- $a Kimura, Takahiro $u School of Medicine, Department of Urology, Jikei University, Tokyo, Japan
- 700 1_
- $a Egawa, Shin $u School of Medicine, Department of Urology, Jikei University, Tokyo, Japan
- 700 1_
- $a Papalia, Rocco $u Department of Urology, Campus Bio-Medico University, Rome, Italy
- 700 1_
- $a Carrion, Diego M $u Department of Urology, La Paz University Hospital, Madrid, Spain $u European Society of Residents in Urology (ESRU), Arnhem, the Netherlands
- 700 1_
- $a Fiori, Cristian $u School of Medicine, Division of Urology, Department of Oncology, San Luigi Hospital, University of Turin, Orbassano, Turin, Italy
- 700 1_
- $a Shariat, Shahrokh F $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia $u Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan $u Department of Urology, Weill Cornell Medical College, New York, NY, USA $u Department of Urology, University of Texas Southwestern, Dallas, TX, USA $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Esperto, Francesco $u Department of Urology, Campus Bio-Medico University, Rome, Italy $u European Society of Residents in Urology (ESRU), Arnhem, the Netherlands
- 700 1_
- $a Pradere, Benjamin $u Department of Urology, Medical University of Vienna, Vienna, Austria
- 773 0_
- $w MED00208300 $t Minerva urology and nephrology $x 2724-6442 $g Roč. 74, č. 3 (2022), s. 292-301
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34308608 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220720 $b ABA008
- 991 __
- $a 20220804134630 $b ABA008
- 999 __
- $a ok $b bmc $g 1822028 $s 1169475
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 74 $c 3 $d 292-301 $e 20210726 $i 2724-6442 $m Minerva urology and nephrology $n Minerva Urol Nephrol $x MED00208300
- LZP __
- $a Pubmed-20220720
